Alameen et al. European Journal of Biomedical and Pharmaceutical Sciences www.ejbps.com 581 ASSESSMENT OF OSTEOPOROSIS IN PATIENTS WITH PROSTATE CANCER USING COMPUTED RADIOGRAPHY Ayman S. Z. Alwi, Suhaib Alameen*, Mohamed E. M. Gar-Elnabi and Yousif S. A. Mukhtar College of Medical Radiological Science, Sudan University of Science and Technology, Khartoum, Sudan. Article Received on 19/10/2016 Article Revised on 09/11/2016 Article Accepted on 30/11/2016 INTRODUCTION Prostate carcinoma is one of the most common cancers in men worldwide. [1,2] Bone is a preferred and sometimes the only, site for prostate cancer metastases, which occur in more than 80% of men with advanced prostate cancer. [3,4] In addition to bone metastases, bone loss resulting from previous orchiectomy or hormonal therapies that lower or block androgen activity may contribute to an increased risk of fracture, pain and other skeletal complications. [5–8] Complications from bone metastases are a major cause of morbidity in patients with prostate carcinoma, causing pain, spinal cord compression, pathologic fractures and abnormalities in serum calcium levels. [9] There are several available methods for treatment of patients with PCa, such as active surveillance, resection, radiotherapy and androgen deprivation. Gonadotropin- releasing hormone analogs may be indicated as adjunctive therapy in the treatment of metastases or as the therapy of choice in biochemical recurrence of primary disease. [10] From the age of 40 on, there is deterioration in bone health. Maternal family history of osteoporosis, smoking, diabetes mellitus, alcoholism and drug use. Although the risk to bone health is recognized, usually patients using GnRHaare not evaluated for osteoporosis. Often the bone mineral density (BMD) before the start of antiandrogenic therapy (ADT) is not performed and in many cases, analysis of bone health is performed only after a major adverse outcome (fracture) has occurred increase the risk of developing osteoporosis. [11-13] and bone loss resulting from previous orchiectomy or hormonal therapies that lower or block androgen activity may contribute to an increased risk of fracture, pain and other skeletal complications. [14-17] Complications from bone metastases are a major cause of morbidity in patients with prostate carcinoma, causing pain, spinal cord compression, pathologic fractures, and abnormalities in serum calcium levels. [18] MATERIAL AND METHOD The data collected from Radiation and Isotopes Center of Khartoum (RICK) and Antalyia Diagnostic Center, where 200 patients, used x.ray machines (philps and shemadzu), patients osteoporosis with prostate cancer imaging with spine and hip x.ray examinations analysing the image with Interactive Data Language IDL software version 6.1 to measure the grey level variation of images SJIF Impact Factor 3.881 Research Article ejbps, 2016, Volume 3, Issue 12, 581-584. European Journal of Biomedical AND Pharmaceutical sciences http://www.ejbps.com ISSN 2349-8870 Volume: 3 Issue: 12 581-584 Year: 2016 *Corresponding Author: Dr. Suhaib Alameen College of Medical Radiological Science, Sudan University of Science and Technology, Khartoum, Sudan. ABSTRACT In this paper we assessment of osteoporosis in patients with prostate cancer using computed radiography, the Bone metastases are a common cause of morbidity in patients with prostate carcinoma. Imaging bone metastases from prostate cancer presents several challenges. The lesions are usually sclerotic and appear late on the conventional X-ray. patient’s osteoporosis with prostate cancer imaging with x.ray and the images analysing by Interactive Data Language IDL software version 6.1 to measure the grey level variation of x.ray images with spine and hip examinations, data was available for 200 patients with x.ray hip and spine examinations , 100 normal and 100 osteoporosis patients with hip and spine x.ray. The results show that the mean of up normal and normal CR for hip regions was 2526.43±310.63 and 619.67±86.39, and for normal and up normal CR spine the mean was 1988±592.44 and 598.77±73.44. and by using T.Test show that there is significant difference between normal and up normal CR for hip regions. and between normal and up normal CR spine. Linear regression results show that the rate of change between normal and up normal hip decreasing, and same for normal and up normal CR spine. Conclusion: there is significant difference between normal and up normal CR for hip regions, and between normal and up normal CR spine, and the rate of change between normal and up normal hip decreasing, for normal and up normal CR spine. KEYWORDS: Osteoporosis, prostate cancer, Computed Radiography.